FDA Places Partial Clinical Hold on Some Trials of Novartis Gene Therapy Zolgensma

FDA holds Novartis Trials for their Gene Therapy Zolgensma Novartis
acknowledged today that the FDA has now imposed a partial hold on
clinical trials for intrathecal administration of AVXS-101, the gene
therapy that won the FDA's first approval for treating some forms of
the spinal muscular atrophy (SMA) in May under the name Zolgensma®.
The […]

The post FDA Places Partial Clinical Hold on Some Trials of Novartis
Gene Therapy Zolgensma appeared first on Rasayanika .

https://www.rasayanika.com/2019/10/31/fda-holds-novartis-trials-for-their-gene-therapy-zolgensma/

News